MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, TPST had -$6,766K decrease in cash & cash equivalents over the period. -$6,779K in free cash flow.

Cash Flow Overview

Change in Cash
-$6,766K
Free Cash flow
-$6,779K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-3,511 -18,730
Depreciation expense
66 135
Stock-based compensation expense
61 2,481
Non-cash lease expense
279 539
Non-cash interest and other expense, net
1 76
Prepaid expenses and other assets
-243 -339
Accounts payable
-3,794 2,266
Accrued expenses and other liabilities
134 -3,166
Interest payable
0 -59
Operating lease liabilities
-258 -348
Cash used in operating activities
-6,779 -16,467
Purchase of property and equipment
0 0
Cash used in investing activities
0 0
Proceeds from the issuance of common stock, net of issuance costs
0 5,013
Proceeds from the issuance of pre-funded warrants, net of issuance costs
0 1,858
Repayment of loan
0 6,426
Proceeds from the issuance of common stock under equity plan awards
13 34
Cash provided by financing activities
13 479
Net decrease in cash, cash equivalents and restricted cash
-6,766 -15,988
Cash and cash equivalents at beginning of period
30,711 -
Cash and cash equivalents at end of period
7,957 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Tempest Therapeutics, Inc. (TPST)

Tempest Therapeutics, Inc. (TPST)